12th October 2023
These results could aid the treatment of individuals most at risk of aggressive skin cancer.
Read more5th September 2023
Dr Özgen Deniz and Dr Benjamin Werner are part of a team shortlisted for these prestigious awards
Read more23rd September 2022
New research, co-led by Dr Benjamin Werner from Barts Cancer Institute at Queen Mary University of London, indicates that the circular DNA structures present in around a third of cancers lead to extensive genetic diversity within tumours, giving them the ability to adapt rapidly to environmental stress and resist targeted cancer treatment.
Read more20th July 2022
Congratulations to Dr Audrey Lumeau, Postdoctoral Researcher at Barts Cancer Institute, Queen Mary University of London, who has received a Career Foundation Fellowship from the charity Pancreatic Cancer UK to investigate chromosomal instability in pancreatic cancer and its role in therapy resistance.
Read more6th May 2022
Yorkshire Cancer Research has announced a £3.1 million grant for research led by Ranjit Manchanda to investigate the risks, benefits, and feasibility of introducing population-based genetic testing for ‘all’ women to find out if they are at high risk of cancer. Thousands of women living in Yorkshire and other parts of the UK will be offered tests as part of the PROTECT (Population based germline testing for early detection and cancer prevention) clinical trial.
Read more6th January 2022
Researchers from Barts Cancer Institute at Queen Mary University of London, the Moffitt Cancer Center and the University of Southern California, have developed a new method that measures subtle changes to the genetic code of cells (called DNA methylation) to study the dynamics of what happens to cells within our bodies over time. The new method, published in Nature Biotechnology, provides a way to measure the birth and death of human cells, making it possible to trace cell lineage and evolution.
Read more